Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
NCT04374578 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2022-03-31
Summary
Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2 diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.
Conditions
Interventions
- DRUG
-
Dulaglutide 1.5 MG/ML
Dulaglutide 1.5Mg qw sc injection for 4 weeks
Sponsors & Collaborators
-
Shanghai Zhongshan Hospital
lead OTHER
Principal Investigators
-
Xiaoying Li, MD · Fudan University
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-08
- Primary Completion
- 2021-01-31
- Completion
- 2021-06-30
Countries
- China
Study Locations
More Related Trials
-
GLP-1 and Hypoglycemia
NCT01858896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
NCT04034524 ·Status: UNKNOWN
-
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
NCT00993720 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Glucose Variability in Subclinical Hypertrophy
NCT02748434 ·Status: TERMINATED ·Phase: NA
-
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
NCT01790308 ·Status: UNKNOWN ·Phase: PHASE4
-
Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes
NCT06671340 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
NCT05297045 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
GLP-1 Signaling in Truncally Vagotomized Subjects
NCT02940184 ·Status: UNKNOWN ·Phase: NA
-
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649 ·Status: COMPLETED ·Phase: PHASE3
-
Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
NCT05478707 ·Status: SUSPENDED ·Phase: PHASE2
-
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
NCT03948347 ·Status: UNKNOWN ·Phase: NA
-
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
NCT03444142 ·Status: UNKNOWN ·Phase: PHASE4
-
GLP-1 Infusion and Long-Time Fasting
NCT00285896 ·Status: COMPLETED ·Phase: NA
-
Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT03954873 ·Status: COMPLETED ·Phase: NA
-
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
NCT03426085 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
NCT04687514 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
NCT00437918 ·Status: COMPLETED ·Phase: PHASE4
-
Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
NCT03668470 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects
NCT02147925 ·Status: COMPLETED ·Phase: PHASE4
-
Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
NCT04854083 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
NCT01508923 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
NCT03590626 ·Status: COMPLETED ·Phase: NA
-
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
NCT05305794 ·Status: RECRUITING ·Phase: PHASE3